com 76 77 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Directors Report: Our Governance Other Disclosures Principal Activities and Business Review Acquisitions The Company acts as a holding company to all the Groups subsidiaries.
The Group operates under four segments split between The acquisitions during the year under review are as follows: Pharmaceuticals and Services.
Date of Pharmaceuticals comprise three segments: Acquisition Detail Consideration A cash consideration of 8.03 million Canadian Dollars.
January 2012 HY-50 The worldwide rights excluding European Pharmaceuticals: markets and sells licensed branded pharmaceuticals and specialist pet foods to the veterinary The consideration was funded from the Groups Canada to HY-50 were acquired from profession in Europe.
It is a licensed manufacturer of both Dechras own branded products and products for third party existing cash resources Bexinc Limited.
intra-articular or intravenous treatment US Pharmaceuticals: markets and sells a range of endocrine, ophthalmic, dermatological and equine products into North of lameness in horses caused by joint America.
dysfunction Research and Development: develops and licenses Dechras own branded veterinary product portfolio of novel and generic pharmaceuticals and specialist pet diets.
May 2012 Eurovet Animal An expert in developing, registering, Consideration of 135 million on a cash free debt free The fourth segment, Services, distributes veterinary products, including pharmaceuticals, specialist pet diets and instruments to Health B. V. producing and marketing added value, basis.
The consideration was funded from the Rights veterinary practices within the United Kingdom.
It also provides histology, pathology, haematology, chemistry and microbiology own label companion and farm animal Issue and additional debt facilities services to veterinary practices.
veterinary pharmaceutical medicines The Chairmans Statement and the Directors Business Review can be found on pages 8 to 39 and includes: Rights Issue and Share Capital a description of the principal risks and uncertainties faced by the Group: The issued share capital of the Company for the year is set out in note 23 to the Financial Statements on page 122.
As at the end of an analysis of the development and performance of the Companys business during the financial year: the financial year, 86,870,176 fully paid ordinary shares were in issue which included 379,864 ordinary shares issued during the year in connection with the exercise of options under the Companys share option schemes.
20,040,653 ordinary shares New Ordinary the position of the Companys business at the end of the financial year: Shares were offered by way of a Rights Issue at an issue price of 300 pence per share, raising approximately 58.2 million net of main trends and factors likely to affect the future development, performance and position of the Companys business: and underwriting commission.
The Rights Issue was made on the basis of 3 New Ordinary Shares for every 10 existing ordinary shares.
financial and non-financial key performance indicators used to measure the Groups performance.
The New Ordinary Shares were issued on 16 May 2012 fully paid and rank pari passu in all respects with the existing ordinary Results and Dividends shares.
The results for the year and financial position at 30 June 2012 are shown in the Consolidated Income Statement on page 83 and The New Ordinary Shares represented less than one-third of the issued share capital prior to the Rights Issue and were issued Consolidated Statement of Financial Position on page 85.
The Directors recommend the payment of a final dividend of 8.50 pence under an authority given at the Annual General Meeting held on 4 November 2011. per share which, if approved by Shareholders, will be paid on 23 November 2012 to Shareholders registered at 9 November The holders of shares are entitled to receive dividends when declared, to receive the Companys Report and Accounts, to attend 2012.
The date the shares will become ex-dividend is 7 November 2012.
An interim dividend of 3.77 pence per share restated to and speak at general meetings of the Company, to appoint proxies and to exercise voting rights.
There are no restrictions on take into account the bonus element of the Rights Issue was paid on 10 April 2012, making a total dividend for the year of 12.27 transfer or limitations on the holding of shares in the Company, nor are there any requirements to obtain prior approval in respect pence 2011: 11.12 pence restated for the bonus element of the Rights Issue.
The total dividend payment is 10,125,000 2011: of any transfer of shares.
The Directors are not aware of any agreements which limit the transfer of shares or curtail voting rights 8,039,000. attached to those shares.
Research and Development At the Annual General Meeting of the Company held on 4 November 2011, the Company was authorised to purchase up to The Group has a structured development programme with the aim of identifying and bringing to market new pharmaceutical 6,645,665 of its ordinary shares, representing 10% of the issued share capital of the Company as at 15 September 2011.
Investment in development is seen as key to further strengthen the Groups competitive position.
Further information in were purchased under this authority during the financial year.
A resolution will be put to Shareholders at the forthcoming Annual relation to product development can be found on pages 17 to 19.
The expense on this activity for the year ended 30 June 2012 General Meeting to renew this authority for a further period of one year.
Under the proposed authority shares purchased may be was 5,735,000 2011: 5,221,000 and a further 447,000 2011: 1,025,000 was capitalised as development costs.
either cancelled or held in treasury.
Payment to Suppliers The Directors require authority from Shareholders to allot unissued share capital to the Company and to disapply Shareholders The Company does not follow any code of practice or standard regarding the payment of suppliers but seeks to agree the terms of statutory pre-emption rights.
Such authorities were granted at the 2011 Annual General Meeting, and also at the General Meeting payment with suppliers prior to the placing of business and it is the Companys policy to settle liabilities by the due date.
Resolutions to renew these authorities will be proposed at the 2012 Annual General Meeting.
At 30 June 2012, the Group had an average of 71 days 2011: 60 days purchases outstanding in creditors.
The Company has an average of nil days 2011: nil days purchases outstanding in creditors.
21587-04 10 08 2012 Proof 3 21587-04 10 08 2012 Proof 3 Shareholder Directors Report Directors Report Information Our Accounts Our Governance Our Performance Our Business Dechra Pharmaceuticals PLC www.
com 78 79 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Directors Report: Our Governance Other Disclosures continued Substantial Interests in Voting Rights Directors and Officers Liability In accordance with the requirements in the Listing Rules and the Disclosure Rules and Transparency Rules of the Financial Services The Company maintains an appropriate level of Directors and Officers insurance whereby Directors are indemnified against Authority, the Company had been notified of the following interests exceeding the 3% notification threshold as at the end of the liabilities to third parties to the extent permitted by the Companies Act 2006.
The Directors also benefited from qualifying third party financial year and a date not more than one month before the date of the notice of the Annual General Meeting.
indemnity provision in place during the financial year and at the date of this report.
A copy of the indemnity provision will be available for inspection at the Annual General Meeting.
30 June 2012 16 August 2012 Aggregate Aggregate The contracts of employment or letters of appointment of the Directors and employees of the Company do not provide for Voting Voting compensation for loss of office that occurs because of a takeover.
Rights % Rights % Statement of Directors Responsibilities in respect of the Annual Report and the Financial Statements Schroder Investment Management 15,657,586 18.02 15,357,586 17.68 The Statement of Directors Responsibilities in respect of the Annual Report and the Financial Statements can be found on page 80.
Legal & General Investment Management 5,193,548 5.98 5,062,024 5.83 Fidelity Investments 4,815,763 5.54 4,820,934 5.55 Charitable Contributions Invesco Perpetual 4,536,329 5.22 4,420,925 5.09 Charitable donations made during the year in support of charitable causes in the local communities in which the Group operates Aberdeen Asset Management 4,236,400 4.88 4,546,900 5.23 and those of interest to its employees amounted to 17,796 2011: 6,234.
Further details of donations made by the Group are Threadneedle Investments 3,685,285 4.24 3,666,737 4.22 given on pages 71 to 72.
Rathbones 3,440,853 3.96 3,436,888 3.96 Political Donations and Expenditure Newton Investment Management 3,077,095 3.54 2,942,895 3.39 Scottish Widows 2,988,981 3.44 2,817,651 3.24 No political donations were made during the year ended 30 June 2012.
The Group has a policy of not making any donations to political organisations or independent election candidates or incurring political expenditure anywhere in the world as defined in the Change of Control Significant Agreements Political Parties, Elections and Referendums Act 2000.
As detailed in the Going Concern Statement on page 52 the Group has bank facilities with a syndicate of banks comprising Auditor Lloyds TSB Bank plc, Barclays Bank PLC, Svenska Handelsbanken AB PUBL and HSBC Bank Plc the Banks.
Under the terms A resolution to reappoint KPMG Audit Plc as Auditor of the Company and to authorise the Directors to determine their remuneration of these facilities the Banks can give notice to the Company to repay all amounts outstanding under the facilities and cancel the will be proposed at the forthcoming Annual General Meeting.
commitments where there is a change of control of the Company.
No other agreements that take effect, alter or terminate upon a change of control of the Company following a takeover bid are considered to be significant in terms of their potential impact on the Audit Information business as a whole.
Each of the Directors who held office at the date of the approval of the Directors Report confirms that, so far as he is aware, The Company does not have agreements with any director or employee that provides compensation for loss of office or there is no relevant audit information of which the Auditor is unaware, and each Director has taken all steps that he ought to have employment resulting from a takeover, other than the Company share schemes.
Under such schemes outstanding options and undertaken as a Director to make himself aware of any relevant audit information and to establish that the Auditor is aware of that awards normally vest and become exercisable on a change of control, subject to the satisfaction of any performance conditions at information.
Annual General Meeting The Directors consider that there are no contracted or other arrangements, such as those with major suppliers, which are likely to The 2012 Annual General Meeting of the Company will be held at 10.00 am on 19 October 2012 at Investec Bank plc, 2 Gresham influence, directly or indirectly, the performance of the business and its values.
Furthermore, there are no contracts of significance Street, London EC2V 7QP.
The notice of meeting, which includes special business to be transacted at the Annual General Meeting, subsisting during the financial year between any group undertaking and a controlling Shareholder or in which a Director is or was is included within the Circular accompanying this Annual Report, together with an explanation of the resolutions to be considered at materially interested.
Directors The constitution of the Board and its Committees, together with biographical notes on the Directors, is shown on pages 40 to 41.
By order of the Board Details of Directors attendance at board and committee meetings and a statement on board evaluation are set out in the Corporate Governance Report, Audit Committee Report and Remuneration Report on pages 44 to 54, 56 and 60.
Under the provisions of the UK Corporate Governance Code, all the Directors will retire at the Annual General Meeting and offer themselves for re-election.
Zoe Goulding Company Secretary The interests of the Directors in the share capital of the Company are shown in the Remuneration Report on pages 66 to 68.
During 4 September 2012 the year no Director had a disclosable material interest in any contract or arrangement with the Company or any of its subsidiaries.
Information in relation to the Directors remuneration is disclosed in the Remuneration Report.
The Articles of Association state that a Director may be appointed by an ordinary resolution of the Shareholders or by the Directors, either to fill a vacancy or as an addition to the existing Board but so that the total number of Directors does not exceed the maximum number of Directors allowed pursuant to the Articles of Association.
The maximum number of Directors currently allowed pursuant to the Articles of Association is ten.
The Articles of Association also state that the Board of Directors is responsible for the management of the business of the Company and in doing so may exercise all the powers of the Company subject to the provision of relevant legislation and the Companys constitutional documentation.
The powers of the Directors set out in the Articles of Association include those in relation to the issue and buy-back of shares.
21587-04 10 08 2012 Proof 3 21587-04 10 08 2012 Proof 3 Shareholder Directors Report Directors Report Information Our Accounts Our Governance Our Performance Our Business
